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Purpose: Treatment-related imaging changes (TRICs) after stereotactic radiosurgery (SRS) involves
the benign transient enlargement of radiographic lesions after treatment. Identifying the radiation
dose volumes and conformality metrics associated with TRICs for different post-treatment periods
would be helpful and improve clinical decision making.
Methods: 367 metastases in 113 patients were treated using Gamma Knife SRS between
1/1/2007-12/31/2009. Each metastasis was measured at each imaging follow-up to detect TRICs
(defined as ≥ 20% increase in volume). Fluctuations in small volume lesions (less than 108 mm3)
were ignored given widely variable conformity indices (CI) for small volumes. The Karolinska
Adverse Radiation Effect (KARE) factor, Paddick’s CI, Shaw’s CI, tumor volume (TV), 10 Gy (V10)
and 12 Gy (V12) volumes, and prescription isodose volume (PIV) were calculated.
Results: From 0-6 months, all measures correlated with the incidence of TRICs (p<.001),
except KARE, which was inversely correlated. During the 6-12 month period all measures
except KARE were still correlated. Beyond 12 months, no correlation was found between any
of the measures and the development of TRICs.
Conclusions: All metrics except KARE were associated with TRICs from 0-12 months only. Additional patient
and treatment factors may become dominant at greater times after SRS.
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1. INTRODUCTION

2. METHODS

As the use of stereotactic radiosurgery (SRS) for
brain metastases increases and patient survival lengthens, the incidence of post-SRS adverse radiation
effects (ARE) is also likely to rise. An understanding
of the factors that contribute to ARE development and
how these factors are measured is key to minimizing
its incidence. We have previously reported that ARE
can be clinically silent but can still be problematic
in the form of imaging-based reporting of lesional
regrowth that ultimately is shown to be benign and
transient [1]. We hypothesized that increasing treatment conformality thereby decreasing normal brain
dose should be correlated with a decrease in postSRS treatment related imaging changes (TRICs). All
previously reported indices for measurement of SRS
treatment conformality, including the Shaw conformity index [2], the Paddick conformity index [3,4], the
Karolinska Adverse Radiation Effect (KARE) factor
[5], as well as metrics such as the tumor volume (TV),
prescription isodose volume (PIV), and brain tissue
volume receiving 10 Gy [6] and 12 Gy [7] (see Table
1), were therefore analyzed and compared for ability
to predict TRICs in this single institution prospective
study.

425 metastases in 113 patients were treated using
Gamma Knife SRS at our center between 1/1/200712/31/2009. Plans were retrospectively reviewed by a
single individual and 10 Gy and 12 Gy volumes were
determined by the GammaPlan software. Lesions were
excluded if 2 lesions were within the same dose calculation matrix or if the 10 Gy isodose surfaces for two
lesions intersected. 367 analyzable lesions remained.
Follow-up gadolinium-enhanced T1 weighted volumetric MRI scans were performed every 6-12 weeks for all
patients until death. At the time of treatment and at each
radiographic time point thereafter, lesions were measured in the maximum anterior posterior (AP), right to
left (RL), and cranio-caudal (CC) directions by a single
individual. Lesion volume at each time-point was calculated using the formula (AP x RL x CC)/2 which very
closely approximates the true tumor volume assuming
a spherical lesion (4/3)*π*r3. Incidence and timing of
any post-SRS lesion re-growth was recorded. Based
on our prior work, re-growth beyond a 20% increase
in volume was defined as TRIC [1]. For this study, we
ignored all fluctuations in lesions with a volume less
than 108 mm3 (approximately 6 mm diameter), as
small volume changes in these lesions can result in a

Table 1. Description of tested treatment metrics.

Treatment metric

Description

Note

10 Gy Volume (V10)

Volume receiving 10 Gy

V10 > 10.5 cm3 has been implicated as having a
high risk of radionecrosis [8,9].

12 Gy Volume (V12)

Volume receiving 12 Gy

V12 > 7.9-8.5 cm3 has been implicated as having
a high risk of radionecrosis [8,9].

PIV (Prescription
isodose volume)

Volume of tissue receiving the
prescription dose

TV

Target volume

Also equal to tumor volume, as defined by the
treating physician

Shaw’s conformity
index

PIV/TV

A good measure of prescription conformality
assuming the shape of the PIV and TV are
similar. However, the index does not take into
account prescription or target overlap (or lack
thereof) [2].

Paddick’s conformity (Tumor volume covered by PIV)2 /
index
(TV*PIV)

Combines “under treatment” index and “over
treatment” index [3].

Karolinska Adverse
Radiation Effect
(KARE) factor

If the KARE factor > 4.09, there is a 26% risk of
adverse radiation effects [5].

Volume of local brain receiving 10
Gy / TV

54    Journal of Radiosurgery and SBRT

Vol. 4

2016

Predicting treatment related imaging changes (TRICs)

relatively large apparent percent change but may result
purely from discrepancies in imaging technique (slice
thickness, timing of gadolinium bolus relative to scan
time, and MRI cut variability) or measurement.
For every lesion, the initial TV, PIV, 10 and 12 Gy
volumes, Paddick’s CI, Shaw’s CI, and KARE factor
(V10/TV) were calculated, and the timing of TRIC
development was recorded. Univariate and multivariate
logistic regressions were then used to evaluate the ability of each metric to predict TRICs. Age, sex, histology,
prescription dose and use of WBRT were also analyzed
for influence on TRIC incidence. The entire population
of lesions was initially analyzed. Secondary analyses
were performed on each quartile of lesion size and on
a subset of lesions > 1 cm3 in volume. Finally, a cohort
of patients matched to the cohort of Lippitz et al. by
survival time (> 9 months post treatment), lesion size (>
0.5 cm3), and V10 (3.4 – 42 cm3) was analyzed. In order
to compare the results to the analysis of ARE by Lippitz
et al., only TRICs occurring > 6 months post treatment
were considered for this subset analysis.

3. RESULTS
3.1. Incidence and Timing of TRIC development
In 367 metastases, the overall rate of TRICs was
18.8%. This is somewhat lower than our previously
reported data [1], potentially due to the addition of
exclusion criteria for lesions in close proximity with
overlapping 10 Gy volumes and ignoring fluctuations
in very small lesions, as described above. There was
no correlation between TRIC development and age,
gender, histology, marginal prescription dose, or use of
WBRT on univariate analysis. Increasing survival duration, however, was correlated with an increased likelihood of developing TRICs.
The majority of TRICs for the whole patient group
occurred within 6 months of SRS (11.4%), followed by
TRICs occurring between 6-12 months (6.2%) and then

> 12 months after SRS (1.1%) (Table 2). In patients
surviving > 9 months with lesions measuring greater
than 0.5 cm3 (as reported by Lippitz et al.), timing of
TRICs remained highest within 6 months. However, for
the subset of patients surviving > 9 months with lesions
measuring less than 0.5 cm3, the peak TRIC incidence
occurred between 6-12 months. Smaller lesions thus
had both delayed occurrence and decreased overall
likelihood of TRICs.
3.2. Correlations between treatment metrics and
incidence of TRICs
All metrics correlated as expected with incidence of
TRICs, except KARE, which we found to be inversely
correlated with TRICs (Table 3). Median KARE indices were smaller for those patients with a TRIC (6.38)
compared to those without (8.68, p<.001). Knowing that
smaller lesions and treatment volumes are less likely to
result in a TRIC, we assumed that the inverse correlation
was due to limitation of collimator size causing higher
KARE values in such lesions. We then arbitrarily analyzed the subset of lesions with a volume greater than 1.0
cm3 (n=118) and found that only tumor volume and PIV
were significantly associated with TRIC development.
During the first 6 months after SRS, the more traditional measures (TV, 10 Gy and 12 Gy volume, PIV,
Paddick CI, and Shaw’s CI) correlated with TRICs. A
smaller correlation between these measures and TRICs
was found beyond 6 months. Conversely, within 6
months after SRS, KARE was inversely correlated with
TRICs, but no longer correlated with TRIC development beyond 6 months after SRS. Beyond 12 months,
no correlation was found between any of the measures
and the development of TRICs.
3.3. KARE specific subset
Given the unexpected finding of an inverse correlation with the KARE index, we investigated the subset of

Table 2. Timing of TRIC incidence stratified by survival.

# of lesions

% TRIC 0-6
months

% TRIC 6 – 12
months

% TRIC > 12
months

Total %

< 6 month

n = 88

6.8%

-

-

6.8%

6 – 12 months

n = 129

11.6%

5.4%

-

17%

> 12 months

n = 150

14%

10.7%

2.7%

27.4%

All Patients

n = 367

11.4%

6.2%

1.1%

18.8%

Patient survival
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Table 3. P-Value results from univariate and
multivariate analyses showing correlation between
treatment metrics and TRIC outcome.

Table 4. Risk of ARE and TRIC according to V10
seen at the Karolinska Institute and the current study
population.

Metric

P Value

Lippitz et al.

TV

<0.001

V10

PIV

<0.001

< 3.4 cm

Paddick Index

<0.001

Shaw Index

<0.001

V10

<0.001

V12

<0.001

KARE Index

<0.001†

Current study
ARE Risk

V10

6.3%

< 3.4 cm

3.4 – 42 cm

19%

3.4 – 42 cm

15.4%

> 42 cm

64%

> 42 cm

66.7%

3
3

3

Delineates results inverse to expected correlation and
inverse to previous data.
†

patients in our cohort that would be eligible for direct comparison with Lippitz et al. In that study, patients had to
survive longer than 9 months with a metastasis of greater
than 10 mm diameter (equivalent to volume of > 0.5 cm3
assuming spherical). We found 74 eligible metastases.
Median survival in this patient subset was 15 months,
compared to 21.2 months reported by Lippitz et al. Similar to the previous study, V10 clearly correlated with the
incidence of TRIC development. Our incidence of TRICs
beyond 6 months after SRS in each V10 size category also
closely matches ARE incidence in Lippitz et al (Table
4). However, when looking specifically at intermediate
V10 volumes (3.4 – 42 cm3), our cohort did not have a
decreased rate of TRICs for treatment plans with KARE <
4.09. In fact, the rate of TRICs was slightly worse in this
lower KARE factor range (Table 5), and the KARE factor did not correlate with overall TRIC development in the
entire subset or any quartile within the subset.
3.4. Illustrative examples of TRIC variation
Despite the statistical association between treatment metrics and TRICs, treatment metrics did not
align perfectly with TRIC incidence, and TRICs
remained unpredictable. Two illustrative examples

TRIC Risk
0%

3
3

3

are given in Figure 1, where within the same patient
different lesions with identical calculated treatment
metrics showed different responses. In addition, we
found that late TRICs often occurred with initiation of
systemic therapy independent of any treatment metric.
Two cases are shown in Figures 2 & 3 where initiation of either a small molecule inhibitor of anaplastic
lymphoma kinase (ALK), crizotinib (Figure 2), or an
immune modulating anti-PD1 antibody, nivolumab
(Figure 3), induced dramatic and symptomatic TRICs
after long periods of durable lesion stability.

4. DISCUSSION
We conclude from this study that, as in previously
reported studies, many treatment indices calculated
based on lesion size and volume of irradiated brain
are correlated with risk of TRIC development. However, when the data was stratified by time after SRS, it
became evident that this correlation was most significant in the first 6 months after SRS, less significant in
the 6-12 months after SRS, and then no longer correlated beyond 12 months after SRS. This may explain
why previous studies have not been able to correlate
treatment metrics with risk of ARE.
Although TRIC incidence was highest in the first
6 months after SRS, nearly 40% of the TRICs we
observed occurred after 6 months, clearly after periods of stable disease. While regrowth was presumed

Table 5. Risk of ARE and TRIC in lesions with V10 between 3.4 cm3 and 42 cm3 stratified by KARE index < 4.09
vs. > 4.09 seen at the Karolinska Institute and the current study.

Current Study

Lippitz et al.

Lesions with V10 between 3.4 cm and 42 cm3
3

KARE Index

ARE Risk

KARE Index

TRIC Risk

< 4.09

3.45%

< 4.09

20%

> 4.09

26%

> 4.09

15%
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Figure 1. Two similar brain metastases in a patient with breast cancer (1) and another patient with melanoma
(2). Lesions in each respective patient were in similar locations in the brain and were treated on the same date
with identical prescription doses. The measurements shown are the maximum tumor diameter for each lesion.
Calculated treatment metrics are shown and KARE indices were nearly identical. Lesions were closely followed for
approximately one year via MRI and demonstrate vastly different and unpredictable treatment outcomes.

to be due to radiation effect for all the lesions studied based on their clinical scenario, it is possible
that without histopathologic confirmation regrowth
for some of the lesions could be due to slowly growing tumor recurrence that was not ultimately recognized if the patient died of progressive systemic
disease.
This study was not able to validate the predictive
value of the KARE factor for the development of
TRICs. There may be a variety of reasons why our
results have differed from the original study. Firstly,
there was considerable lack of comparability between
cohorts, with only 20% of our metastases (74/367)
meeting inclusion criteria used by Lippitz et al. In
addition, melanoma patients predominated in our
cohort, while the Karolinska cohort reported by Lippitz et al. was predominantly lung cancer patients (B.
Lippitz, oral communication, May 2014). Volume
measurements methods were also different between
the 2 studies, and inter-institutional treatment planning
variations such as PTV margin around the tumor and
number of shots per lesion, etc. may also explain the
differences in results. Finally, 65% of our metastases

(238 / 367) had a TV <0.5 cm3, and lesions with small
TV will tend to have high KARE indices because even
the smallest collimator size (4 mm) for the Gamma
Knife will not permit highly conformal treatments for
small TVs. As TV appears to be a dominant predictor of TRICs, this may explain the inversion correlation observed between the KARE factor and TRICs in
our original analysis. However, even after eliminating
these smaller lesions and analyzing only those lesions
that met the inclusion criteria used by Lippitz et al.,
we were still unable to validate the use of KARE for
predicting TRICs in lesions with V10 from 3.4-42 cm3
or any quartile of lesion size.
In addition to SRS treatment metrics, other patient
factors may need to be incorporated into risk modeling. Specific patient and tumor genetics may play a
role in SRS outcome and thus likelihood of TRICs. It
has been previously reported that lung cancer patients
with ALK amplifications or EGFR mutations have
extremely high rates of lesional control in the brain
after SRS [10]. In addition, as use of more novel targeted agents have emerged, we have seen profound
systemic influences possibly inducing imaging abnor-
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Figure 2. 28 year old female with ALK translocated lung cancer was treated with SRS to numerous brain lesions.
Post treatment radiographic time course is shown for 3 of the treated lesions. Robust symptomatic and unexpected
radionecrosis was seen in two of the three lesions after treatment with crizotinib after 1 year or more of lesion
stability. Patient is alive without viable intracranial disease or intracranial radiographic progression.

malities in the brain after long periods of stability. The
phenomenon of “Radiation Recall” has been observed
and described previously. It is mostly seen as an acute
inflammatory reaction confined to previously irradiated areas that can be triggered when chemotherapy
agents (most commonly doxorubicin, docetaxel, paclitaxel, gemcitabine and capecitabine) are administered

after radiotherapy [11,12,13,14]. Although one review
indicated that the time interval between the completion of radiation therapy and the administration of
cytotoxic chemotherapy is between 6 and 37 days in
patients that develop recall [11], other reports indicate
periods within 90 days [15], to 15 or even 25 years
after radiotherapy [16,17]. While most documented

Figure 3. 40 year old female with metastatic melanoma was treated with SRS to 32 brain lesions. Post treatment
radiographic time course is shown for 8 of the treated lesions. While 3 lesions presented with radionecrosis
needing intervention possibly associated with either vemurafenib or ipilimumab, the rest remained stable or
improved for up to one year. However, robust symptomatic and abrupt simultaneous radionecrosis was seen in all
of the remaining 29 lesions including 5 shown below shortly after initiation of anti-PD1 therapy, nivolumab. Patient is
alive without viable intracranial disease or intracranial radiographic progression.
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cases are limited to the skin due to ease and convenience of diagnosis, there are cases of CNS radiation
recall in the current literature [14,18]. In addition to
classical cytotoxic chemotherapy, many oncologically
useful small molecule targeted therapeutics and monoclonal antibodies have shown profound effects either
with or after radiotherapy [19,20,21,22,23,24]. Given
the relative lack of information regarding the interaction of novel systemic therapies and SRS related
TRICs, this area needs further study.
In addition to novel targeted therapy, we believe
immunologic therapy can induce TRICs. Residual
long term inflammation and necrosis in brain tissue
as well as permanent local disruptions in the vasculature can be seen on histopathology after SRS [25].
The appearance of these inflammatory and necrotic
changes are plausibly influenced by agents that can
influence immune response. For example, anti-PD-1
therapy (nivolumab) could theoretically enhance
immune activity and surveillance in a location harboring chronic inflammation and possibly tumor cell
antigens (viable or non-viable), leading to an inflammatory response resulting in a TRIC, as in our patient
(see Figure 3). Similarly, ipilimumab, through targeting CTLA-4, an inhibitor of cytotoxic T cells, can produce a similar response on imaging.
The potential for immune agents to induce TRICs
is also consistent with other prior work that indicates
a more intense inflammatory response for controlled
tumors vs. poorly controlled tumors [26,27,25]. For
neoplasms well-controlled by SRS, histopathology
within the irradiated tumor volume is consistent with a
moderate-to-intense inflammatory cell reaction – prominently CD68-positive macrophages and CD3-positive
T-lymphocyte populations – that is otherwise missing
or sparse in poorly controlled neoplasms with recurrent
disease [26]. Given that many of our lesions are “well
controlled”, it is plausible that an active and dynamic
radiation-induced and immunotherapy enhanced
immune response could be responsible for some of the
TRICs seen.
In conclusion, our study is unique as it describes
SRS related TRICs that can occur after profoundly
long periods of stable disease. We found that while
the set of metrics available in the literature is useful
and should be used for SRS plan evaluation within 12
months of SRS, we were unable to validate their use
beyond 12 months. Thus, the influence of systemic
therapy on the incidence of TRICs may be overpowering the predictive value of treatment related metrics after 12 months. Due to complex heterogeneity
between individual patients, tumor genetics, brain
location, and non-targeted and targeted systemic treatments, we need to continue to look for better predictors of long term TRICs after SRS.
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